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Earlier primate studies revealed that oral transmission of immunodeficiency viruses can occur at all ages
[R. M. Ruprecht et al., J. Infect. Dis. 179(Suppl. 3):S408–S412, 1999]. Using a stock of pathogenic simian-
human immunodeficiency virus, SHIV89.6P, we compared the 50% animal infectious dose needed to achieve
systemic infection after oral challenge in newborn and older infant or juvenile rhesus macaques. Unexpectedly,
the older monkeys required a 150-fold-lower virus challenge dose than the neonates (P  3.3  105). In
addition, at least 60,000 times more virus was needed to achieve systemic infection in neonates by the oral route
than by the intravenous route (P < 1  105). Thus, route of inoculation and age are important determinants
of SHIV89.6P infectivity in rhesus macaques.
Oral transmission of simian immunodeficiency virus (SIV)
or simian-human immunodeficiency virus (SHIV) strains in
rhesus monkeys has been used as a model system (1, 2) to study
oral HIV transmission in humans. In human infants, HIV may
be transmitted orally during delivery (17) and through breast-
feeding (18); in adults, oral HIV transmission through sexual
contact has been described (27).
We have previously established a rhesus monkey model to
mimic postnatal HIV transmission through breastfeeding (1);
this model uses nontraumatic oral challenge with cell-free vi-
ruses and allows evaluation of preventive strategies against
milk-borne virus transmission (3, 11, 11a, 13, 15). Several SIV
and SHIV strains with different tropism have been titrated
orally in newborn monkeys to establish reproducible oral chal-
lenge systems (3, 15, 21).
We hypothesized that neonates are more susceptible to in-
fection than older infants, given the neonates’ smaller size and
more immature immune system. Using SHIV89.6P as test vi-
rus, we sought to measure age-related differences in oral virus
transmissibility. SHIV89.6P was derived from the nonpatho-
genic SHIV89.6, which expresses the envelope glycoproteins of
primary, dual tropic HIV89.6 (7). After passage of SHIV89.6
through several rhesus monkeys, the resulting SHIV89.6P be-
came acutely pathogenic, causing profound CD4 T-cell de-
pletion within 2 weeks postchallenge (20). Our SHIV89.6P
stock had been generated in rhesus monkey peripheral blood
mononuclear cells (PBMC) and contained 2.6  104 50%
tissue culture infectious doses (15).
To determine the 50% animal infectious dose (AID50) in
neonatal rhesus monkeys, infants born by normal vaginal de-
livery were exposed orally during the first 3 days of life to
various dilutions of the SHIV89.6P stock. After all oral intake
was withheld for 4 h, 3 ml of the diluted virus was placed
nontraumatically at the back of the tongue. Blood was col-
lected and real-time reverse-transcriptase PCR, as described
previously (14), was used to analyze viral loads in plasma at
weeks 0, 1, 2, and 4 postinoculation. In addition, PBMC of the
virus-exposed monkeys were monitored repeatedly for 6 or 7
weeks by cocultivation, as described previously (2). In monkeys
challenged as neonates, a virus dilution of 1:40 resulted in
systemic infection, whereas a dilution of 1:100 did not (Table
1). The statistical method of Spouge (23) was used to deter-
mine the AID50 of the SHIV89.6P stock in this group of ani-
mals. The AID50 for the oral route was approximately 3.3 
102 (95% confidence interval [CI], 7.59  103 to 1.42 
101) (Table 2). The results of monkey PBMC cocultures
confirmed these data (Table 3); no virus was detected for
animals RCu-6 and RZt-6 (Table 3). As expected, infected
infants demonstrated marked losses of CD4 T cells compared
to the published values obtained from age-matched, uninfected
rhesus monkeys (8) (Table 1).
To determine the susceptibility of older infants to orally
inoculated SHIV89.6P, the same virus stock was used; the
protocol included careful oral exams prior to oral inoculation.
Animals between the ages of 11 and 23 months were enrolled
(Table 1); no significant oral pathology was noted in any ani-
mal. A virus dilution of 1:6,000 resulted in systemic infection in
both animals that had been given this dilution, whereas a
dilution of 1:10,000 did not. The AID50 was 2.2  10
4 (95%
CI, 5.8  105 to 9.6  104) (Table 2). When this dose was
compared with that required to infect half of the newborn
infants by the oral route, we found that 150-fold more virus was
needed to infect the latter (P  3.3  105). Thus, our titra-
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tions revealed a highly significant age dependence in the rhesus
monkeys’ susceptibility to oral SHIV89.6P inoculation.
Next, we assessed the different doses of the same SHIV89.6P
stock required to achieve systemic infection of neonatal rhesus
monkeys after intravenous (i.v.) versus oral inoculation. For
i.v. challenge, the injected volume was 1 ml of virus at various
dilutions. The highest virus dilution (1:2,000,000) still resulted
in systemic infection of the neonate (Table 1). Because no
virus-challenged animal remained uninfected, the determina-
tion of the AID50 with i.v. challenge (AID50-iv) according to
the method of Spouge (23) was problematic. In a simulation,
we assumed that the next animal inoculated with the same
dilution of 1:2,000,000 would remain uninfected. Based on this
worst-case scenario, we estimated an AID50-iv for neonates at
5  107 (95% CI, 9.14  108 to 4.5  106) (Table 2);
however, even less virus may have been required. This esti-
mated AID50-iv was compared to the AID50 of 3.3  10
2 for
the oral route in neonates (Table 2). According to these AID50
values, at least 60,000-fold more virus was needed to achieve
infection by the oral route than by the i.v. route (P  1 
105). In a previous study (4), we had compared oral versus i.v.
challenges in adult rhesus monkeys, using minimal infectious
doses of SIVDeltaB670 as parameters. We found that the ratio
of the minimal oral dose to the minimal i.v. dose (rmin-adult)
was approximately 1,000 (4). In the present neonatal study, the
estimated rmin-neonate was at least 50,000 (Table 1), a value
similar to that obtained when AID50 values were compared
(Table 2). Together, the rmin values reflect a relative 50-fold
resistance of the oral route in neonatal monkeys compared to
that in adults. It would be interesting to perform oral and i.v.
challenge studies in neonatal macaques with SIVDeltaB670 to
confirm this notion, as this virus differs in its coreceptor usage
from that of SHIV89.6P. SIVDeltaB670, a primary biological
isolate (5), was shown to use CCR5 but not CXCR4 (9).
In addition, we sought to compare peak viral RNA loads at
week 2 after SHIV89.6P challenge in our three cohorts (Table
1). Only animals with systemic infection were included in the
analysis. No dose response between virus inocula and peak
viral RNA levels was observed in any of the three cohorts. We
then compared viral load distribution in the five neonates ver-
sus that of the seven older animals infected orally. The peak
viral RNA load was 10-fold higher in the older animal cohort
TABLE 1. SHIV89.6P titrations in neonatal and older rhesus monkeys
Route of
inoculation Animal Age Dilution
Systemic infection
present
Peak viral RNA
load at week 2
(RNA copies/ml)
CD4 T cells (cells/l)a
at week 2 at week 4
Oral RGt-6 1 day 1 Yes 110,750 1,240 397
RHt-6 1 day 1:10 Yes 5,094,275 82 115
RJv-6 1 day 1:20 Yes 15,036,775 2,880 150
RJu-6 3 days 1:20 Yes 1,237,798 0 0
RUz-6 2 days 1:40b Yes 164,852 NDc 63
RCu-6 1 day 1:100 No 200 3,726 2,435
RZt-6 1 day 1:1,000 No 50 NDc NDc
RSt-7 11 months 1:6 Yes 363,726,500 27 42
RAu-7 11 months 1:10 Yes 23,319,530 1,489 1,176
RSs-7 12 months 1:100 Yes 27,688,625 68 66
RGn-7 16 months 1:1,000 Yes 1,922,178 180 110
REu-7 18 months 1:3,000 Yes 14,342,610 382 578
RAy-7 18 months 1:6,000 Yes 8,824,345 1,058 1,323
RPj-7 23 months 1:6,000 Yes 12,564,025 562 483
RRd-7 16 months 1:10,000 No 50 3,421 3,504
Intravenous RZv-6 1 day 1:2,000 Yes 44,761,565 14 NDc
RVv-6 1 day 1:20,000 Yes 52,827,105 23 14
RWz-6 2 days 1:200,000 Yes 25,133,855 54 NDc
RTe-7 1 day 1:2,000,000 Yes 484,813 110 0
a The absolute number of CD4 T cells in naive infants at week 2 was 3,025; at week 3, 3155; and at week 8, 2,585 (8).
b The ratio of the minimal oral dose (1:40) to the assumed minimal i.v. dose (1:2  106) in neonates was at least 50,000.
c ND, not determined.
TABLE 2. SHIV89.6P AID50 as a function of age and route of inoculation
Route of
inoculation Age of monkey AID50
a 95% CI P valued
Oral 1–3 days 3.3 102 7.6  103–1.4  101
11–23 months 2.2 104 5.8  105–9.6  104 3.3  105b
Intravenous 1–2 days 5.0 107 9.1  108–4.5  106 1.0  105c
a The AID50 was determined by the statistical method of Spouge (23).
b The oral AID50 in neonates compared to the oral AID50 in older animals.
c The oral AID50 in neonates compared to the i.v. AID50 in neonates.
d The P values listed are significant with the Bonferroni correction.
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than in neonates (two-sided P value  0.048 by the Wilcoxon
rank-sum test) (16). In addition, we compared the viral RNA
load distribution of the five orally infected neonates versus that
of the four i.v.-infected neonates. No statistically significant
differences were seen when the same nonparametric test was
used. Thus, neither route of inoculation nor virus dose influ-
enced peak viral RNA loads once systemic infection had been
achieved in neonatal monkeys. In contrast, peak viral RNA
loads differed significantly as a function of age after oral inoc-
ulation.
To summarize, our data showed for the first time that mon-
keys of different ages differ significantly in their susceptibility
to oral SHIV89.6P challenge; in newborns, an oral virus dose
more than 2 logs higher than that for older monkeys was
required to achieve systemic infection. The underlying mech-
anisms for the differential susceptibility could involve a number
of factors.
Saliva contains a number of nonspecific factors with antiviral
activity, such as lactoferrin, secretory leukocyte protease inhib-
itor (SLPI), mucins, proline-rich proteins, and cystatins (22).
Possibly, in our experiments age-related differences in saliva
composition led to different levels of viral inactivation in the
oral cavity. Interestingly, a recent study found that human
neonates had higher concentrations of salivary SLPI than older
infants; in a group of uninfected infants breast-fed by HIV-
positive mothers for 1 month, a significant association was seen
between higher SLPI levels in saliva and a decrease in HIV
transmission (10). The site(s) of viral entry after oral inocula-
tion is unknown; the virus could enter the submucosal tissues
in either the oral cavity, esophagus, stomach, or intestine (4,
19, 24, 25). When highly concentrated SIV was applied directly
to tonsils in rhesus monkeys, virus entry through these lym-
phoid tissues and subsequent rapid spread to local and re-
gional lymph nodes were demonstrated (24). These results,
however, do not rule out that the virus can also pass across
intact mucosal surfaces at other levels in the gastrointestinal
tract. It is possible that age-related differences in mucosal
permeability influenced SHIV89.6P transmission after oral in-
oculation.
Age-related differences in the virus target cell population,
such as higher levels of chemokine coreceptor expression
and/or the state of cellular activation, may account for the
significantly higher peak viral RNA loads we observed in neo-
natal monkeys versus those in older monkeys with systemic
infection after oral challenge. The latter animals were not only
more susceptible to the oral challenge but also seemed to
replicate SHIV89.6P to higher levels once systemic infection
had been established. We postulate that systemic infection is
achieved once the virus inoculum exceeds a predetermined
threshold, which differs for the various routes of inoculation
and is age dependent, according to our new data. However,
once this threshold has been surpassed and systemic infection
is established, there is no association between the inoculum
size and peak viral RNA; this lack of a dose response has been
observed previously (6) and is not surprising for an outbred
population of primates.
The levels of lentiviral receptor and coreceptor expression in
tissues are key determinants for virus entry into target cells and
subsequent spread to distant sites (26). In the present study, we
inoculated neonatal and older monkeys with dual tropic
SHIV89.6P, a virus that utilizes either CCR5 or CXCR4 in
vitro. A previous study sought to correlate the coreceptor us-
age of three variants of HIV89.6, all of which were dual tropic
when tested in vitro, with their coreceptor usage when assayed
ex vivo in human tonsillar explants (12). In this tissue micro-
environment, one HIV89.6 variant surprisingly preferred
CXCR4, another used CXCR4 and CCR5 equally, and the
third exhibited a preference for CCR5; the two X4 strains were
more cytopathic than the one preferring CCR5 in tonsillar
explants. In our rhesus monkey study, the actual coreceptor(s)
used by SHIV89.6P to initiate replication after oral inoculation
is unknown, but given its pronounced pathogenicity in this
species, preferred usage of CXCR4 would not be unexpected.
Age-related variations in CXCR4 or CCR5 expression levels in
gastrointestinal tissues could have influenced the transmissibil-
ity of SHIV89.6P in our animals. Thus far, no data have been
published regarding chemokine receptor expression in mucosal
tissues as a function of age in rhesus macaques. However, the
pattern of chemokine receptor expression in the central ner-
vous system of rhesus monkey neonates differed from that of
older infants; CCR5 and CXCR4 expression increased signif-
icantly from birth to 9 months of age on neurons and glia (26).
Similar age-related increases in chemokine expression could
account for the age-related differences in oral SHIV89.6P
transmission in our study.
In summary, our primate studies have revealed a significant
difference in the susceptibility of neonatal and older rhesus
macaques to oral SHIV89.6P transmission. It will be important
to test whether virus strains with different tropism, especially
SHIV strains encoding R5 HIV envelope genes, exhibit similar
age dependence for transmission through the oral route or
other mucosal routes.
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